2019
Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected
Dosani T, Covut F, Pinto R, Kim BG, Ali N, Beck R, Maitta R, Downes K, Fox R, Reese J, de Lima M, Malek E. Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected. Leukemia & Lymphoma 2019, 60: 2199-2206. PMID: 30845862, DOI: 10.1080/10428194.2019.1573367.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAutograftsBenzylaminesChemotherapy, AdjuvantCyclamsFemaleHematopoietic Stem Cell MobilizationHeterocyclic CompoundsHumansInduction ChemotherapyLenalidomideLeukapheresisMaleMiddle AgedMultiple MyelomaNeoadjuvant TherapyPeripheral Blood Stem Cell TransplantationRegression AnalysisRetrospective StudiesTransplantation, AutologousTreatment OutcomeConceptsImpact of lenalidomideLens exposureClinical implicationsPeripheral stem cell collectionAutologous stem cell transplantationTransplant-eligible patientsStem cell transplantationStem cell collectionSignificant clinical implicationsErythroid progenitorsHematopoietic myeloidInduction therapyLens usePBSC graftsCell transplantationMultiple myelomaPBSC collectionPlerixafor useLenalidomidePatientsCell collectionGraftMobilization agentsHematopoietic progenitorsExposure
2017
Host-related immunodeficiency in the development of multiple myeloma
Dosani T, Mailankody S, Korde N, Manasanch E, Bhutani M, Tageja N, Roschewski M, Kwok M, Kazandjian D, Costello R, Burton D, Zhang Y, Liewehr D, Steinberg SM, Maric I, Landgren O. Host-related immunodeficiency in the development of multiple myeloma. Leukemia & Lymphoma 2017, 59: 1127-1132. PMID: 28792255, PMCID: PMC6750254, DOI: 10.1080/10428194.2017.1361026.Peer-Reviewed Original ResearchConceptsMultiple myelomaLymphocyte subsetsCD57- subsetImmune biomarkersDevelopment of MMMyeloma precursor diseaseNK cell proportionNovel immune biomarkersProgression of SMMMultiparametric flow cytometrySMM patientsImmune changesImmune patternsClinical guidancePrecursor diseaseCell proportionFlow cytometryMGUSPotential markerImmunodeficiencySequential changesMyelomaPatientsPrecursor conditionsProgressionSignificance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma
Dosani T, Covut F, Beck R, Driscoll J, de Lima M, Malek E. Significance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma. Blood Cancer Journal 2017, 7: e579-e579. PMID: 28665418, PMCID: PMC5520407, DOI: 10.1038/bcj.2017.60.Peer-Reviewed Original Research
2015
The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies
Dosani T, Carlsten M, Maric I, Landgren O. The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies. Blood Cancer Journal 2015, 5: e306-e306. PMID: 25885426, PMCID: PMC4450330, DOI: 10.1038/bcj.2015.32.Peer-Reviewed Original ResearchMeSH KeywordsBone Marrow CellsHumansImmune SystemImmunotherapyKiller Cells, NaturalMultiple MyelomaT-LymphocytesT-Lymphocytes, RegulatoryConceptsDevelopment of MMMultiple myelomaT cellsImmune systemNatural killer T cellsRegulatory T cellsKiller T cellsNatural killer cellsConventional T cellsΓδ T cellsCellular immune systemImmune subsetsNK cellsKiller cellsPeripheral bloodUndetermined significanceImmune cellsMonoclonal gammopathyImmune componentsTumor evolutionBone marrowMyelomagenesisImmunotherapyPrecursor conditionsCurrent literature